Malignant Mesothelioma – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Malignant Mesothelioma – Pipeline Review, H2 2019’, provides an overview of the Malignant Mesothelioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Malignant Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma

– The report reviews pipeline therapeutics for Malignant Mesothelioma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Malignant Mesothelioma therapeutics and enlists all their major and minor projects

– The report assesses Malignant Mesothelioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Malignant Mesothelioma”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AbbVie Inc

ADC Therapeutics SA

Agios Pharmaceuticals Inc

Aldeyra Therapeutics Inc

Almac Discovery Ltd

Amphera BV

AnGes Inc

Apollomics Inc

Applied Research using OMIC Sciences SL

Argenx SE

ArQule Inc

Ascentage Pharma Group International

AstraZeneca Plc

Atara Biotherapeutics Inc

Aurigene Discovery Technologies Ltd

Bayer AG

BerGenBio ASA

Biocad

Biogen Inc

Bionomics Ltd

Boehringer Ingelheim International GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CanBas Co Ltd

Canget BioTekpharma LLC

Checkpoint Therapeutics Inc

Chiome Bioscience Inc

Clovis Oncology Inc

CStone Pharmaceuticals Co Ltd

Deciphera Pharmaceuticals Inc

Delta-Fly Pharma Inc

Eli Lilly and Co

EnGeneIC Ltd

Epigene Therapeutics Inc

Epizyme Inc

F. Hoffmann-La Roche Ltd

FKD Therapies Oy

Flag Therapeutics Inc

Genelux Corp

GlaxoSmithKline Plc

H2Biologics Inc

Harpoon Therapeutics Inc

Hebei Senlang Biotechnology Inc Ltd

Horizon Therapeutics PLC

Hutchison MediPharma Ltd

IDAC Theranostics Inc

Incyte Corp

Infinity Pharmaceuticals Inc

Inhibrx Inc

Inventiva

Invion Ltd

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

L.E.A.F. Pharmaceuticals LLC

Laboratoires Pierre Fabre SA

Leucid Bio Ltd

LipoSeuticals Inc

MacroGenics Inc

Marino Biotechnology Co Ltd

MELEMA Pharma GmbH

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Minneamrita Therapeutics LLC

Molecular Partners AG

MolMed SpA

Morphotek Inc

MTG Biotherapeutics Inc

NeoTX Therapeutics Ltd

Novartis AG

Oasmia Pharmaceutical AB

Oncology Venture U.S. Inc

Ono Pharmaceutical Co Ltd

OSE Immunotherapeutics

Pharma Mar SA

PlumeStars Srl

Polaris Pharmaceuticals Inc

Seattle Genetics Inc

SELLAS Life Sciences Group Inc

Shanghai GeneChem Co Ltd

Targovax ASA

TCR2 Therapeutics Inc

TRACON Pharmaceuticals Inc

TREAT U SA

Ube Industries Ltd

VasGene Therapeutics Inc

Venus Remedies Ltd

Verastem Inc

Y’s Therapeutics Co Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Malignant Mesothelioma - Overview 6

Malignant Mesothelioma - Therapeutics Development 7

Malignant Mesothelioma - Therapeutics Assessment 22

Malignant Mesothelioma - Companies Involved in Therapeutics Development 36

Malignant Mesothelioma - Drug Profiles 68

Malignant Mesothelioma - Dormant Projects 733

Malignant Mesothelioma - Discontinued Products 736

Malignant Mesothelioma - Product Development Milestones 737

Appendix 751

List of Tables

“List of Tables

Table 1: Number of Products under Development for Malignant Mesothelioma, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 7: Number of Products under Development by Universities/Institutes, H2 2019

Table 8: Products under Development by Companies, H2 2019

Table 9: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 10: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 11: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 12: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 13: Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 14: Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 15: Products under Development by Universities/Institutes, H2 2019

Table 16: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Table 17: Number of Products by Stage and Target, H2 2019

Table 18: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 19: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Table 20: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Table 21: Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019

Table 22: Number of Products by Stage and Mechanism of Action, H2 2019

Table 23: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 24: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Table 25: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Table 26: Number of Products by Stage and Route of Administration, H2 2019

Table 27: Number of Products by Stage and Molecule Type, H2 2019

Table 28: Malignant Mesothelioma – Pipeline by AbbVie Inc, H2 2019

Table 29: Malignant Mesothelioma – Pipeline by ADC Therapeutics SA, H2 2019

Table 30: Malignant Mesothelioma – Pipeline by Agios Pharmaceuticals Inc, H2 2019

Table 31: Malignant Mesothelioma – Pipeline by Aldeyra Therapeutics Inc, H2 2019

Table 32: Malignant Mesothelioma – Pipeline by Almac Discovery Ltd, H2 2019

Table 33: Malignant Mesothelioma – Pipeline by Amphera BV, H2 2019

Table 34: Malignant Mesothelioma – Pipeline by AnGes Inc, H2 2019

Table 35: Malignant Mesothelioma – Pipeline by Apollomics Inc, H2 2019

Table 36: Malignant Mesothelioma – Pipeline by Applied Research using OMIC Sciences SL, H2 2019

Table 37: Malignant Mesothelioma – Pipeline by Argenx SE, H2 2019

Table 38: Malignant Mesothelioma – Pipeline by ArQule Inc, H2 2019

Table 39: Malignant Mesothelioma – Pipeline by Ascentage Pharma Group International, H2 2019

Table 40: Malignant Mesothelioma – Pipeline by AstraZeneca Plc, H2 2019

Table 41: Malignant Mesothelioma – Pipeline by Atara Biotherapeutics Inc, H2 2019

Table 42: Malignant Mesothelioma – Pipeline by Aurigene Discovery Technologies Ltd, H2 2019

Table 43: Malignant Mesothelioma – Pipeline by Bayer AG, H2 2019

Table 44: Malignant Mesothelioma – Pipeline by BerGenBio ASA, H2 2019

Table 45: Malignant Mesothelioma – Pipeline by Biocad, H2 2019

Table 46: Malignant Mesothelioma – Pipeline by Biogen Inc, H2 2019

Table 47: Malignant Mesothelioma – Pipeline by Bionomics Ltd, H2 2019

Table 48: Malignant Mesothelioma – Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Table 49: Malignant Mesothelioma – Pipeline by Boston Biomedical Inc, H2 2019

Table 50: Malignant Mesothelioma – Pipeline by Bristol-Myers Squibb Co, H2 2019

Table 51: Malignant Mesothelioma – Pipeline by Calithera Biosciences Inc, H2 2019

Table 52: Malignant Mesothelioma – Pipeline by CanBas Co Ltd, H2 2019

Table 53: Malignant Mesothelioma – Pipeline by Canget BioTekpharma LLC, H2 2019

Table 54: Malignant Mesothelioma – Pipeline by Checkpoint Therapeutics Inc, H2 2019

Table 55: Malignant Mesothelioma – Pipeline by Chiome Bioscience Inc, H2 2019

Table 56: Malignant Mesothelioma – Pipeline by Clovis Oncology Inc, H2 2019

Table 57: Malignant Mesothelioma – Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019

Table 58: Malignant Mesothelioma – Pipeline by Deciphera Pharmaceuticals Inc, H2 2019

Table 59: Malignant Mesothelioma – Pipeline by Delta-Fly Pharma Inc, H2 2019

Table 60: Malignant Mesothelioma – Pipeline by Eli Lilly and Co, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Malignant Mesothelioma, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports